Followers | 194 |
Posts | 34198 |
Boards Moderated | 4 |
Alias Born | 08/30/2018 |
Wednesday, October 05, 2022 1:42:47 PM
Recent BHVN News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:18:10 PM
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 10/02/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 08:06:51 PM
- Biohaven Announces Pricing of $250 Million Public Offering of Common Shares • PR Newswire (US) • 10/01/2024 10:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/30/2024 09:29:09 PM
- Biohaven Announces Proposed Public Offering of Common Shares • PR Newswire (US) • 09/30/2024 08:05:00 PM
- Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine • PR Newswire (US) • 09/30/2024 11:30:00 AM
- Visa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEO • IH Market News • 09/24/2024 10:15:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 01:11:53 PM
- Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) • PR Newswire (US) • 09/23/2024 11:30:00 AM
- Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia • PR Newswire (US) • 09/20/2024 11:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:35:34 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 08/16/2024 08:31:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:25:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:21:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:06:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:17:54 PM
- Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments • PR Newswire (US) • 08/08/2024 08:05:00 PM
- Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day • PR Newswire (US) • 05/29/2024 11:30:00 AM
- Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors • PR Newswire (US) • 05/29/2024 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:42:44 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 05/17/2024 08:41:07 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 08:16:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:14:14 PM
- Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments • PR Newswire (US) • 05/09/2024 08:05:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM